RxDoctor Payments Data

John Cahill, MD

Interventional Cardiology · Elmhurst, ILNPI 1124071337

Payments from drug & device makers

$3,553in general payments, 2019–2025

Across 166 payments — averaging $21.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$764
  • Novartis$512
  • Pfizer$305
  • Amgen$295
  • Boehringer Ingelheim$274
  • Boston Scientific$231
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,540100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,553 in reported general payments places this provider in the 25th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$441,158
Medicare patients
1,477
Services billed
5,709

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban349$395,534
EntrestoSacubitril/Valsartan255$251,745
XareltoRivaroxaban178$197,627
Repatha SureclickEvolocumab149$133,244
JardianceEmpagliflozin63$57,661
Praluent PenAlirocumab28$34,333
BrilintaTicagrelor36$30,087
Metoprolol Succinate978$14,774
FarxigaDapagliflozin Propanediol16$12,357
Ezetimibe466$9,818
Atorvastatin Calcium775$8,714
Rosuvastatin Calcium640$7,240
VascepaIcosapent Ethyl18$7,125
NexletolBempedoic Acid15$6,499
ClopidogrelClopidogrel Bisulfate516$5,900

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$305$395,534349 claims
NovartisEntresto$512$251,745255 claims
Johnson & JohnsonXarelto$764$197,627178 claims
Boehringer IngelheimJardiance$274$57,66163 claims
AstraZenecaBrilinta, Farxiga$80$42,44352 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Elmhurst

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →